Merck and Bristol-Myers Squibb recently signed a trial protocol for tumor immunotherapy with Lilly to evaluate the efficacy of their respective combination of PD-1 inhibitor and Eli Lilly, which can be seen as two pharmaceutical giants. A new round of competition in tumor immunotherapy. Merck will test the safety, tolerability and effectiveness of its star tumor suppressor, Keytruda (pembrolizumab), with Lilly's oncology drug through multiple clinical trials. Under the terms of the agreement, Merck will conduct a Phase 2 clinical study of Keytruda and Lilly Alimta (pemetrexed) in the treatment of non-small cell lung cancer. Lilly will be responsible for Phase 1 and Phase 2 clinical trials of Cyramza (ramucirumab)/Keytruda in a variety of oncology therapies, and Phase 1 / 2 clinical trials of necitumumab/Keytruda for the treatment of non-small cell lung cancer. The clinical trials of Bristol-Myers Squibb and Lilly are mainly aimed at its tumor immunopharmaceutical Opdivo (nivolmab) and Lilly's experimental new drug galunisertib (LY2157299) in advanced glioblastoma, hepatocellular carcinoma and non-small cell lung cancer. Potential application value. The second phase clinical evaluation of Lilly's galunisertib is also being carried out by Bristol-Myers, a galunisertib, an oral drug used to treat a variety of advanced or metastatic malignancies. Currently, its efficacy is directed at hepatocellular carcinoma and myeloproliferation. Abnormal syndrome, malignant glioma, and pancreatic cancer. Keytruda and Opdivo are approved by the FDA for the treatment of melanoma, and both Merck and Bristol-Myers have submitted applications for the treatment of non-small cell lung cancer. Merck has announced that Keytruda is expected to be approved for the treatment of non-small cell lung cancer without ALK or EGFR mutations in mid-2015, and Bristol-Myers has also announced that Opdivo can effectively prolong the survival rate of patients with lung cancer. The collaboration between each of them and Lilly has also added a lot of drama to the competition in the field of PD-1 inhibitors. Preserved Fruits,Fruit Preserves,Peach Preserves,Strawberry Preserves COFCO HEBEI INTERNATIONAL TRADING CO., LTD. , https://www.cofcohb.com